NCT04873063View on ClinicalTrials.gov

Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Healthy Adult Male Volunteers
Interventions
DRUG

Beclomethasone dipropionate

BDP 3 mg bid (R product) BDP 6 mg qd (T product)

Trial Locations (1)

37134

Centro Ricerche Cliniche AOU Integrata di Verona - Policlinico Universitario G.B. Rossi, Verona

All Listed Sponsors
lead

SOFAR S.p.A.

INDUSTRY

NCT04873063 - Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers | Biotech Hunter | Biotech Hunter